Literature DB >> 19751703

Preferential increase in the hippocampal synaptic vesicle protein 2A (SV2A) by pentylenetetrazole kindling.

Yukihiro Ohno1, Shizuka Ishihara, Ryo Terada, Miki Kikuta, Nobumasa Sofue, Yoshiko Kawai, Tadao Serikawa, Masashi Sasa.   

Abstract

The present study evaluated the expressional levels of synaptic vesicle protein 2A (SV2A) and other secretary machinery proteins (i.e., soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complexes, Munc18-1, N-ethylmaleimide-sensitive factor (NSF) and soluble N-ethylmaleimide-sensitive factor attachment protein (SNAP)) in a pentylenetetrazole (PTZ) kindling model. Repeated administration of sub-convulsive PTZ (40 mg/kg, i.p.) progressively increased seizure susceptibility in mice and consistently induced clonic seizures in most animals tested at 15 days after the treatment. Western blot analysis revealed that, among the secretary machinery proteins examined, hippocampal SV2A was selectively elevated by PTZ kindling. PTZ kindling-induced SV2A expression appeared region-specific and the SV2A levels in the cerebral cortex or cerebellum were unaltered. In addition, SV2A expression by PTZ kindling was prominent in the hilar region of the dentate gyrus (DG) where GABAergic interneurons are located, but not in other hippocampal regions (e.g., the stratum lucidum of the CA3 and synaptic layers surrounding CA1 or CA3 pyramidal neurons). These findings suggest that PTZ kindling preferentially elevates SV2A expression in the hippocampus probably as a compensatory mechanism to activate the inhibitory neurotransmission.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19751703     DOI: 10.1016/j.bbrc.2009.09.035

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  17 in total

1.  Immunochemical analysis of the expression of SV2C in mouse, macaque and human brain.

Authors:  Amy R Dunn; Carlie A Hoffman; Kristen A Stout; Minagi Ozawa; Rohan K Dhamsania; Gary W Miller
Journal:  Brain Res       Date:  2017-12-21       Impact factor: 3.252

Review 2.  Synaptic vesicle protein 2: A multi-faceted regulator of secretion.

Authors:  Kristine Ciruelas; Daniele Marcotulli; Sandra M Bajjalieh
Journal:  Semin Cell Dev Biol       Date:  2019-03-21       Impact factor: 7.727

3.  Association of Alpha-Soluble NSF Attachment Protein with Epileptic Seizure.

Authors:  Zhiqin Xi; Wanni Deng; Liang Wang; Fei Xiao; Jie Li; Zhihua Wang; Xin Wang; Xiujuan Mi; Na Wang; Xuefeng Wang
Journal:  J Mol Neurosci       Date:  2015-07-09       Impact factor: 3.444

4.  The Expression Alteration of BC1 RNA and its Interaction with Eukaryotic Translation Initiation Factor eIF4A Post-Status Epilepticus.

Authors:  Xiangchang Zeng; Wenjing Zong; Qing Gao; Siyu Chen; Lulu Chen; Guirong Zeng; Weihua Huang; Zhenyu Li; Chang Zeng; Yuanyuan Xie; Xiaohui Li; Bo Xiao; Kai Hu
Journal:  Neurochem Res       Date:  2018-05-17       Impact factor: 3.996

5.  Synaptic Vesicle Protein 2A Expression in Glutamatergic Terminals Is Associated with the Response to Levetiracetam Treatment.

Authors:  Itzel Jatziri Contreras-García; Gisela Gómez-Lira; Bryan Víctor Phillips-Farfán; Luz Adriana Pichardo-Macías; Mercedes Edna García-Cruz; Juan Luis Chávez-Pacheco; Julieta G Mendoza-Torreblanca
Journal:  Brain Sci       Date:  2021-04-23

6.  Levetiracetam reverses synaptic deficits produced by overexpression of SV2A.

Authors:  Amy Nowack; Erik B Malarkey; Jia Yao; Adam Bleckert; Jessica Hill; Sandra M Bajjalieh
Journal:  PLoS One       Date:  2011-12-29       Impact factor: 3.240

7.  A Missense Mutation of the Gene Encoding Synaptic Vesicle Glycoprotein 2A (SV2A) Confers Seizure Susceptibility by Disrupting Amygdalar Synaptic GABA Release.

Authors:  Kentaro Tokudome; Takahiro Okumura; Ryo Terada; Saki Shimizu; Naofumi Kunisawa; Tomoji Mashimo; Tadao Serikawa; Masashi Sasa; Yukihiro Ohno
Journal:  Front Pharmacol       Date:  2016-07-14       Impact factor: 5.810

8.  Expressional analysis of the astrocytic Kir4.1 channel in a pilocarpine-induced temporal lobe epilepsy model.

Authors:  Yuki Nagao; Yuya Harada; Takahiro Mukai; Saki Shimizu; Aoi Okuda; Megumi Fujimoto; Asuka Ono; Yoshihisa Sakagami; Yukihiro Ohno
Journal:  Front Cell Neurosci       Date:  2013-07-05       Impact factor: 5.505

9.  Synaptic vesicle glycoprotein 2A (SV2A) regulates kindling epileptogenesis via GABAergic neurotransmission.

Authors:  Kentaro Tokudome; Takahiro Okumura; Saki Shimizu; Tomoji Mashimo; Akiko Takizawa; Tadao Serikawa; Ryo Terada; Shizuka Ishihara; Naofumi Kunisawa; Masashi Sasa; Yukihiro Ohno
Journal:  Sci Rep       Date:  2016-06-06       Impact factor: 4.379

Review 10.  Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond.

Authors:  Wolfgang Löscher; Michel Gillard; Zara A Sands; Rafal M Kaminski; Henrik Klitgaard
Journal:  CNS Drugs       Date:  2016-11       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.